“Long-Term Evaluation of Infliximab in the Treatment of Persistently Active Juvenile Idiopathic Arthritis Refractory to Conventional Therapy”. 2007. Reumatismo 59 (1): 50-56. https://doi.org/10.4081/reumatismo.2007.50.